Impairing PD1-PDL1 ligation through deletion of PD1 promotes clearance of tumors expressing PDL1 (Chen and Han, 2015) and monoclonal antibodies that target the interaction to overturn PDL1-mediated inhibition of TILs have revolutionized cancer care. This evidence concerns the gene PDCD1 and cancer.